Physiomics Awarded New Contract by GARDP
Physiomics plc has secured a new contract with GARDP Foundation to provide expert consultancy support for optimizing the design of an efficacy trial within their Serious Bacterial Infections programme, with work commencing in January 2026 and expected to conclude within three months. This marks the company's second major client in its Biometrics department, which has surpassed initial projections since its launch, representing a significant milestone and a promising contribution to Physiomics' growth objectives, particularly with its expansion into the infectious disease therapeutic area.
Select text to share a quote on X · sign in to keep highlights & notes in your PYC notes
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract in the biometrics department with a new client, GARDP Foundation ("GARDP"). GARDP is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure sustainable access.
In this project, Physiomics will provide expert consultancy support to GARDP to optimise the design of an efficacy trial in their Serious Bacterial Infections (SBIs) programme. The work for this project is expected to begin January 2026 and is expected to complete within three months.
This project represents an important development in our Biometrics department, being our second major client in this space. We will be providing our client with a strategic partner to support their clinical development plans through optimising design and lean on both the internal expertise at Physiomics, as well as our network of consultants.
Jesse Thissen, Head of Biometrics at Physiomics, commented:
"We're delighted to start our new partnership with GARDP through this project. Utilising our expertise in study design to support clinical development planning aligns perfectly with our mission to help clients make faster, more informed decisions that can help de-risk development and improve outcomes. This project also marks further expansion into new therapeutic areas for Physiomics in Infectious Disease, which has been a target for the Company."
Dr Peter Sargent, CEO of Physiomics, commented:
"This contract award represents a significant milestone for our organisation. Securing our third Biometrics contract since launching the new service line earlier this summer has surpassed our initial projections and underscores the promising contribution this service can make to the Company's growth objectives."
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.